browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
8395f609-3fd6-4cc7-ab6f-7e0158b9404c
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-20 21:14:55
Income (reported)
$60,000
Expenses (reported)
Filing document
Open on lda.senate.gov
Registrant (lobbying firm)

THE MCMANUS GROUP

Consulting

Contact
NATE GASPAR
Phone
+1 434-989-7548
Address
zip:20001, city:Washington, state:DC, street:610 10th St. NW Suite 300
Client

GILEAD SCIENCES, INC.

Client is a biopharmaceutical company that develops medicines in areas of unmet need.

State
CA
Country
US
Government-entity client
false
Effective date
2013-09-09
Issues lobbied + lobbyists (2)

MMM — Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Support for H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

HCR — Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.

Lobbyists:

Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.